 |
|
Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma
Collaborative Ocular Melanoma Study Group Report No. 26
Collaborative Ocular Melanoma Study Group*
Arch Ophthalmol. 2005;123:1639-1643.
Objective To describe the time between treatment for choroidal melanoma and first diagnosis of metastatic disease, sites of metastasis, treatments for metastasis, and time between diagnosis of metastasis and death.
Design Prospective, longitudinal follow-up of patients diagnosed with choroidal melanoma who were enrolled in 2 randomized trials conducted by the Collaborative Ocular Melanoma Study Group.
Methods Systemic and laboratory evaluations were performed during follow-up according to a standard protocol for 2320 patients enrolled in the Collaborative Ocular Melanoma Study trials without evidence of melanoma metastasis or other primary cancer at baseline.
Results Seven hundred thirty-nine patients were diagnosed with at least 1 site of metastasis during follow-up after treatment for choroidal melanoma. Five- and 10-year cumulative metastasis rates were 25% (95% confidence interval, 23%-27%) and 34% (95% confidence interval, 32%-37%), respectively. Liver was the most common site (89%). The death rate following the report of melanoma metastasis was 80% at 1 year (95% confidence interval, 77%-83%) and 92% at 2 years (95% confidence interval, 89%-94%). Overall survival after metastasis did not vary by baseline size of primary tumor nor treatment for metastasis (when known). Long-term survival after diagnosis of metastasis was uncommon; only 8 patients survived 5 or more years.
Conclusion Metastasis rate increased significantly with increasing primary tumor dimensions at time of patient enrollment. Prognosis after metastatic disease remains poor. Effective methods are needed to prevent, diagnose, and treat metastasis from choroidal melanoma.
*Authors: This report was prepared on behalf of the COMS Group by Marie Diener-West, PhD; Sandra M. Reynolds, MA; Donna J. Agugliaro, RN, BSN; Robert Caldwell, PA; Kristi Cumming, RN, MSN; John D. Earle, MD; Barbara S. Hawkins, PhD; James A. Hayman, MD; Ishmael Jaiyesimi, MD; Lee M. Jampol, MD; John M. Kirkwood, MD; Wui-Jin Koh, MD; Dennis M. Robertson, MD; John M. Shaw, MD; Bradley R. Straatsma, MD, JD; and Jonni Thoma, RN, BSN.
Group Information: A list of the Collaborative Ocular Melanoma Study Group as of September 30, 2000, was published in Arch Ophthalmol. 2001;119:961-965.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Carboplatin and Vinorelbine Combined with Subcutaneous Interleukin-2 in Metastatic Melanoma with Poor Prognosis
VUORISTO et al.
Anticancer Res 2009;29:1755-1759.
ABSTRACT
| FULL TEXT
Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma
Ulmer et al.
Clin. Cancer Res. 2008;14:4469-4474.
ABSTRACT
| FULL TEXT
The Future Promise and the Current Reality of Genetic Prognostication in Patients With Uveal Melanoma
Tsai and O'Brien
Arch Ophthalmol 2008;126:413-415.
FULL TEXT
Molecular Characteristics of Liver Metastases from Uveal Melanoma
Meir et al.
IOVS 2007;48:4890-4896.
ABSTRACT
| FULL TEXT
Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment
Markovic et al.
Mayo Clin Proc. 2007;82:490-513.
ABSTRACT
| FULL TEXT
Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma
Schuster et al.
Clin. Cancer Res. 2007;13:1171-1178.
ABSTRACT
| FULL TEXT
Proton Beam Irradiation of Uveal Melanomas: The First 30 Years The Weisenfeld Lecture
Gragoudas
IOVS 2006;47:4666-4673.
FULL TEXT
From the Library
Br. J. Ophthalmol. 2006;90:394-394.
FULL TEXT
|
